Cellogen Therapeutics awaits CDSCO approval for Phase I trials on innovative CAR-T product targeting B cell leukemia.

A new artificial intelligence tool could help doctors determine which prostate cancer patients are most likely to benefit ...

This therapy targets multiple tumor-specific antigens, offering improved treatment precision for blood cancer patients, and ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.

Researchers at the Friedrich Loeffler Institute and the University of Greifswald in Germany have gained new insights into how the African swine fever (ASF) virus infiltrates the immune system of ...

The study, published in The Lancet Haematology, has revealed that the injection had a 73% response rate among Indian patients ...

The future of medicine is being shaped by a confluence of factors at play. If there are worries galore around drug resistant ...

Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ...

About PD-1 Inhibitors PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body’s ability to ...

Here is everything you need to know about the recent case of human coronavirus case in Kolkata. Understanding the symptoms of ...